In addition to helping to elucidate a biologic basis of heart failure, Dr. Stamler has developed and tested new therapeutic modalities to preserve and improve cardiac function. He is one of the inventors of the patents underlying the drug portfolio that includes CDP-1050, which Duska recently licensed from Duke University and Johns Hopkins University.
CDP-1050 is an investigational drug candidate for the treatment of heart failure. The drug is designed to correct nitric oxide and redox imbalance in the failing heart and the cardiovascular system. CDP-1050 has a dual mechanism of action to inhibit the creation of excessive reactive oxygen radicals and restore nitric oxide to physiologic levels. The principal therapeutic target is the ryanodine receptor, the main ion channel in the heart that supplies the calcium necessary for the heart to contract. CDP-1050 is expected to enter a Phase 2 clinical study early next year.
"With its strong scientific underpinnings and commercial orientation, the Duska team is the perfect group to organize and manage the CDP-1050 Phase 2 proof-of-concept study in heart failure patients," Dr. Stamler commented. "CDP-1050 is pioneering a new paradigm of heart failure treatments by directly repairing molecular damage to the heart, the root cause of heart failure."
"Dr. Stamler has developed proprietary investigational drugs for heart
failure based on his comprehensive and profound understanding of the signal
transduction defects underlying the disease. We believe that his formal
involvement with Dus
|SOURCE Duska Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved